4.1 Introduction

The World Health Organization (WHO) Classification of Tumors of Central Nervous System (CNS) provided an update in 2016 nearly 10 years after the 2007 version to help more systematically categorize brain tumors. The revised system for the first time uniquely included molecular and genetic parameters of the individual tumor types, in addition to the histological features. Accordingly, each tumor is now identified by both its phenotype (based on histology), and genotype (based on its molecular and genetic parameters) [1].

4.2 Goals of the Revised Classification

The goals are multi-fold: (1) To resolve some of the confusion created by classifying brain tumors based only on histology, (2) Provide greater diagnostic accuracy, (3) Aid better treatment strategies, and (4) Allow for an improved assessment of the prognosis based on the specific tumor type.

4.3 Background

A classic example of uncertainty created in the past where tumors were classified based only on histology included the group “oligoastrocytoma.” These were tumors which exhibited features of both oligodendroglioma and astrocytoma on histology, and were therefore lumped together as oligoastrocytomas [2–4]. Accordingly, their management was not definitive which in turn influenced their prognosis. Categorizing this tumor group based on the underlying 1p/19q codeletion (genetic mutation) status allows them to be clearly distinguished almost always into either (1p/19q-codeleted) oligodendroglioma or (1p-19q-intact) astrocytoma [5–8]. Only a few tumors cannot be categorized into either group, and are known as oligoastrocytoma, NOS (not otherwise specified) [1, 9, 10]. This clear distinction allows more accurate diagnosis, which therefore influences more appropriate tumor specific treatment strategies, and a better predictor for the overall prognosis. Another perplexing prognostic feature was noted in terms of the overall survival of certain low grade gliomas, which surprisingly were noted to perform much worse than Grade III astrocytomas. This can now be explained based on their IDH-mutation status, with IDH-wildtype Grade I Gliomas performing much poorer than IDH-mutant Grade III astrocytomas [5, 6]. Thus, it is the mutation status which influences the overall prognosis much more than the histology.

Utilizing the background above, the discussion below will mention the salient features of how the Revised 2016 classification influences our understanding of brain tumors focusing on infiltrating gliomas in adults, gliomas in children, and the introduction of certain new tumor types. A description of all CNS tumor types included in the Revised 2016 Classification of CNS tumors is beyond the scope of this text.
### 4.4 Infiltrating Gliomas in Adults

Several mutations are associated with infiltrating gliomas in adults. Of these, some of the important ones include IDH mutation, 1p-19q codeletion, and TP53 mutation status [11].

The primary deterministic mutation includes the IDH-mutation status—presence suggests IDH-mutant, and absent an IDH-wildtype tumor [12].

### 4.5 IDH-Mutant gliomas

There are two types of IDH mutation, IDH1- and IDH2-mutated tumors. An overwhelming majority of such tumors are IDH1 mutated. Less than 3% of IDH-mutated tumors are exclusively IDH2-mutant tumors [13].

#### 4.5.1 Clinical Relevance and Prognosis

IDH-mutant tumors are seen more commonly in the middle-aged population (30–60 years of age), than IDH-wildtype tumors which are more frequently seen in the older population (>60–65 years of age). The overall survival of IDH-mutant tumors is far better than IDH-wildtype tumors. In fact, as mentioned previously, low grade (grade I by histology) IDH-wildtype gliomas have an overall survival close to that of grade IV IDH-wildtype glioblastomas, but much worse than grade III IDH-mutant gliomas. It is the IDH-mutation status which is the driving force in terms of overall prognosis, much more than the histological grade. Furthermore, even among the Grade IV glioblastomas, it has been noted that IDH-mutant glioblastomas have an overall survival much better than IDH-wildtype glioblastomas. Supporting this is the fact that most IDH-mutant glioblastomas are the secondary type, while most IDH-wildtype glioblastomas are the de novo or primary type [14].

It is a known fact in glioma surgery that wider the resection, better is the overall survival. Knowing preoperatively that the tumor is an IDH-mutant type can influence the surgeon for a more complete surgical resection, including the FLAIR signal abnormality surrounding the enhancing mass [15]. The radiologist by suggesting the genetic profile preoperatively can accordingly influence the extent of surgical resection.

#### Key Point
- IDH-mutant tumors, seen more commonly in the middle-aged population (third to sixth decade of life), have a far better overall survival than IDH-wildtype tumors, which are seen more commonly in the older patients (>60–65 years of age).

### 4.5.2 Radiological Features

Both IDH1 and IDH2 mutations change the role of IDH in the citric acid cycle. This results in accumulation of 2-HG within tumor cells. 2-hydroxyglutarate (2-HG) can be detected on MR spectroscopy and is therefore considered to be the imaging hallmark of all IDH-mutant tumors [16]. However, reliable detection is challenging, and is possible only at some select centers with special MR spectroscopists on site [17–19].

It has been noted that most IDH-mutated tumors occur in a single lobe, frontal lobe being the most common, followed by temporal, parietal, and occipital lobes [20]. Most such tumors demonstrate a sharp margin and inhomogenous but mild contrast enhancement. In contrast, IDH-wildtype tumors are frequently multilobar in location. Preferred site involves the insula with extension into the adjacent temporal, frontal, and parietal lobes [20, 21]. In terms of their morphological appearance, these IDH-wildtype tumors demonstrate ill-defined margins with the adjacent brain. Necrosis and moderate to intense heterogenous, especially peripheral enhancement is seen in the IDH-wildtype tumors (Fig. 4.1). The presence of necrosis, more intense enhancement, and ill-defined margins suggests more oxygen demand, more robust neoangiogenesis, and infiltrative nature of the wildtype tumors than their IDH-mutant counterparts.

### 4.6 1p/19q-Codeletion

IDH-mutant gliomas can subsequently be classified into those which are 1p/19q-codeleted tumors or 1p/19q-intact tumors. Of these, those gliomas which are 1p/19q-codeleted are the oligodendrogliomas, while those which are 1p/19q-intact are astrocytomas. Astrocytomas typically also show TP53 mutation, a mutation which is never seen in oligodendrogliomas, another distinguishing feature that separates these two entities. As mentioned previously, this 1p/19q-codeleted status and TP53 mutation help clearly separate the confusing oligoastrocytoma group into either oligodendroglioma or astrocytoma (which was not possible based on histological features alone), which helps better manage these patients.

#### Key Point
- 1p/19q-codeletion status in an IDH-mutant tumor is diagnostic of oligodendroglioma; 1p/19q-intact status with TP53 mutation is diagnostic of astrocytoma.

#### 4.6.1 Clinical Relevance and Prognosis

It has been shown in two large randomized control trials that chemotherapeutic agents including procarbazine, lomustine,
and vincristine (PCV) when added to radiation therapy significantly improve the overall survival in patients with 1p/19q-deleted tumors when compared with radiation therapy alone [22, 23]. This is now the standard of care for all 1p/19q-codeleted oligodendrogliomas.

4.6.2 Radiological Features

Frontal lobe is the most common location of 1p/19q-codeleted tumors. Other common sites include the parietal and occipital lobes. In contrast, 1p/19q-intact tumors are

**Fig. 4.1** A 69-year-old male with change in mental status. (a) Coronal T2WI demonstrates a heterogenous centrally necrotic mass in the left insular region extending to involve the frontal lobe. (b) Axial FLAIR image demonstrates FLAIR signal abnormality surrounding this lesion which shows indistinct margin with the adjacent brain. (c) Axial T1 post-contrast image demonstrates heterogenous but predominantly peripheral intense enhancement. (d) Corresponding axial DSC (dynamic susceptibility contrast) perfusion map demonstrates increased relative blood volume from the enhancing component of this lesion. Diagnosis: IDH-wildtype glioblastoma
seen most often in the temporal lobes and the insular cortex. In terms of their morphological appearance, 1p/19q-codeleted tumors demonstrate a more heterogeneous appearance. Also, calcification is a common feature of such tumors (Fig. 4.2). In fact, presence of florid calcification and enhancement favors a higher grade (Grade III) oligodendroglioma [24, 25]. An intact margin favors a 1p/19q-intact tumor, while ill-defined margins can be seen in both types. T2-FLAIR mismatch sign corresponding to a predominantly hyperintense signal of the mass on T2WI and corresponding hypointense signal on FLAIR has a high positive predictive value for 1p/19q-intact tumors (Fig. 4.3) [26].

**Fig. 4.2** A 48-year-old man with seizures. (a) Axial T2WI demonstrates a heterogenous mass involving the right frontal lobe. (b) Corresponding axial T1 post-contrast image demonstrates heterogenous but minimal enhancement. (c) Axial CT scan from the same patient demonstrates multiple arcs of calcification within this mass. Diagnosis: Oligodendroglioma, IDH-mutant, 1p/19q codeleted tumor
**4.7 Gliomatosis Cerebri**

Gliomatosis cerebri as a specific tumor subtype was included in the 2007 version of the WHO Classification of CNS tumors. This term is deleted from the 2016 Update. A diffusely infiltrating non-enhancing tumor extending to involve three or more lobes is no longer to be considered as gliomatosis cerebri. It is recognized as a diffuse glioma type, with its subtype dependent on further genetic, molecular testing and histological evaluation [1].

**Key Point**
- Gliomatosis cerebri as a tumor type is no longer recognized.

**4.7.1 Gliomas in Children**

Gliomas in children have been known to behave differently than those seen in the adult population. This is related to the fact that mutations seen commonly in gliomas in adults including IDH mutation and 1p/19q-codeletion occur only uncommonly in children [27]. In fact, the two common mutation types commonly seen in children, include BRAF mutation and histone H3-K27 m-mutation.

**4.8 BRAF Mutation**

These tumors are usually well-circumscribed and carry an excellent prognosis.

**4.9 Radiological Features**

Cystic lesion with a mural enhancing nodule are common imaging features (Fig. 4.4). This mutation type encompasses pilocytic astrocytoma, pilomyxoid astrocytoma, and ganglioglioma [5, 11].

**Key Point**
- BRAF mutation is one of the most common mutations seen in the pediatric population, and includes tumor types such as pilocytic astrocytoma, pilomyxoid astrocytoma, and ganglioglioma.
4.10 Histone H3-K27m-Mutant Tumors

These are diffuse midline gliomas (previously known as diffuse infiltrating pontine glioma) and carry an extremely poor prognosis. Location of this tumor type makes it difficult to biopsy these tumors or attempt a surgical resection [28, 29]. Radiation and chemotherapy are not particularly helpful.

4.10.1 Radiological Features

Brainstem (pons) is the most common location. Other common locations include thalami and spinal cord. As previously described this is a diffusely infiltrating lesion which results in secondary expansion of the structure involved. Only minimal enhancement is typically seen. Occasionally however, heterogeneous enhancement and cyst(s) can be seen [30]. Leptomeningeal dissemination is seen in about one-third of all such patients.

Key Point
- H3K27M-mutant glioma now includes the previously known diffuse infiltrating pontine glioma, and carries a dismal prognosis.

4.11 Solitary Fibrous Tumor (SFT) and Hemangiopericytoma (HPC)

Both these tumors share the same genetic feature which includes genomic inversion at the 12q13 locus, fusing the NAB2 and STAT6 genes. Hence, these two previously distinct tumors are now combined as SFT/HPC tumor. Of these, the SFT/HPC Grade I is a slowly growing tumor with excellent prognosis, while SFT/HPC Grade II and III have a slightly poor prognosis, carry a high risk to recur following resection, and are associated with metastasis [27].

4.12 New Tumors and Patterns

4.12.1 Multinodular and Vacuolating Neuronal Tumor

This rare entity has received mention in the 2016 Revised CNS Tumor Classification. It is unclear if it is a distinct tumor or in the tumor-dysplasia category. It carries an excellent prognosis and is believed to be a “Leave-me-alone” lesion.
4.12.2 Radiological Features

It is known to occur anywhere in the brain, but commonly in the supratentorial compartment and especially in the frontal and temporal lobes. On morphological appearance, the lesion is seen as a cluster of FLAIR and T2 bright lesions typically in the subcortical white matter. Involvement of the overlying cortex and periventricular white matter has been reported. The lesion appears dark on T1WI and does not demonstrate contrast enhancement or diffusion restriction. No susceptibility is seen [31].

4.13 Diffuse Leptomeningeal Glioneuronal Tumor

This is a rare glioneuronal neoplasm mainly seen in children. It is largely localized to the leptomeningeal compartment. Oligodendroglioma like tumor cells are seen on histology.

4.13.1 Radiological Features

Diffuse, somewhat heterogenous leptomeningeal enhancement is noted. Frequently the basal cisterns are involved with associated extensive involvement of the subarachnoid space along the surface of the cord. Secondary hydrocephalus is commonly noted [32]. Parenchymal involvement can also be seen. When present, it is seen to involve the spinal cord and the brain stem.

4.14 Conclusion

The Revised 2016 classification of CNS tumors by including the genetic profile improves diagnostic accuracy of brain tumors. This allows neuro-oncologists and the surgeons to optimize treatment strategies targeted to the specific tumor type, thus allowing for a better prognosis, and improved overall survival. The neuroradiologist by identifying the imaging phenotype of the particular glioma genotype plays an important role in guiding the clinical team in their treatment planning.

References

1. Louis DN, et al. The 2016 World Health Organization classification of tumors of the central nervous system. Acta Neuropathol. 2016;131(6):803–20.
2. Louis DN, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.
3. Giannini C, et al. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol. 2001;60:248–62.
4. van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol. 2010;120:297–304.
5. Brat DJ. Cancer genome atlas research network, et al. Comprehensive integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372:2481–98.
6. Metellus P, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol. 2010;120(6):719–29.
7. Sahm F, et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 2014;128:551–9.
8. Wiestler B, et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 2014;128:561–71.
9. Huse JT, et al. Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true “oligoastrocytoma”? Acta Neuropathol. 2015;129:151–3.
10. Wilcox P, et al. Oligoastrocytomas: throwing the baby out with the bathwater? Acta Neuropathol. 2015;129:147–9.
11. Appin CL, et al. Molecular pathways in gliomagenesis and their relevance to neuropsychiatric diagnosis. Adv Anat Pathol. 2015;22(1):50–8.
12. Cohen AL, et al. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep. 2013;13(5):345.
13. Smits M, et al. Imaging correlates of adult glioma genotypes. Radiology. 2017;284:316–31.
14. Yan H, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73.
15. Beiko J, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncology. 2014;16(1): 81–91.
16. Esmaili M, et al. 2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping. Transl Oncol. 2013;6(2):92–8.
17. Andronesi OC, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D cor-

Take Home Messages

• IDH-mutated tumors are more solid in their imaging profile, and demonstrate less enhancement than IDH-wildtype counterparts.
• 1p/19q-codeleted tumors are more heterogenous in their imaging appearance, and exhibit calcification more frequently than their 1p/19q-intact (noncodeleted) counterparts.
• BRAF-mutant tumors are seen more commonly in the pediatric population. These include pilocytic astrocytoma, pilomyxoid astrocytoma, and ganglioglioma in their molecular profile spectrum.
• H3K27M-mutant tumors are also seen more commonly in the pediatric population, but are more diffuse and aggressive. These mutant tumors encompass the previously described diffuse infiltrating pontine glioma spectrum of tumors.
relation magnetic resonance spectroscopy. Sci Transl Med. 2012;4(116):116ra4.
18. Bertolino N, et al. Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3T: a phantom study. Phys Med. 2014;30(6):702–7.
19. Pope WB, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurosci. 2012;107(1):197.
20. Wang Y, et al. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas. Eur J Neurol. 2015;22(2):348–54.
21. Smits M, et al. Imaging of oligodendroglioma. Br J Radiol. 2016;89(1060):20150857.
22. van den Bent MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow up on EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344–50.
23. Cairncross G, et al. Phase III trial of chemotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9401. J Clin Oncol. 2013;31(3):337–43.
24. van den Bent MJ, et al. Diffuse infiltrating oligodendroglioma and astrocytoma. J Clin Oncol. 2017;35(21):2394–401.
25. Khalid L, et al. Imaging characteristics of oligodendrogliomas that predict grade. AJNR Am J Neuroradiol. 2012;33(5):852–7.
26. Patel SH, et al. T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res. 2017;23(20):6078–85.
27. Johnson DR, et al. 2016 updates to the WHO brain tumor classification system: what the radiologist needs to know. Radiographics. 2017;37:2164–80.
28. Khuong-Quang DA, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012;124(3):439–47.
29. Solomon DA, et al. Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol. 2016;26(5):569–80.
30. Aboian MS, et al. Imaging characteristics of pediatric diffuse midline gliomas with histone H3K27M mutation. AJNR Am J Neuroradiol. 2017;38(4):795–800.
31. Nunes RH, et al. Multinodular and vacuolating neuronal tumor of the cerebrum: a new “leave me alone” lesion with a characteristic imaging pattern. AJNR Am J Neuroradiol. 2017;38(10):1899–904.
32. Preuss M, et al. Disseminated oligodendroglial-like leptomeningeal tumors: preliminary diagnostic and therapeutic results for a novel tumor entity. J Neuro-Oncol. 2015;124(1):65–74.